Whether spurred by the actions of local challenger Natco Pharma Limited or not, Eli Lilly and Company is now pursuing voluntary licensing in India for its rheumatoid arthritis drug baricitinib (available internationally as Olumiant) used in combination with remdesivir as a COVID-19 therapy.
Lilly’s seemingly changed approach is significant – indeed has been termed "reactionary" by some industry experts – given that local...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
